Medicare Advantage Star Ratings are determined by narrow margins, where small improvements in key measures can decide whether a plan crosses critical Star threshold levels and unlocks substantial revenue through Quality Bonus Payments (QBP). Starting with the 2026 Star Ratings, the Centers for Medicare & Medicaid Services (CMS) reduced the weight of patient experience/complaints and access measures, including CAHPS measures, from 4 times to 2 times. This change applies to the patient experience category, which encompasses CAHPS surveys for member feedback on care access, timeliness, coordination, and satisfaction.
Despite the reduced weighting, CAHPS remains a vital factor in the Medicare Advantage Star Ratings framework. It remains a critical multiplier, determining whether gains in clinical quality and operational performance translate into higher Star Ratings and, ultimately, revenue. A modest 0.2-point gain in CAHPS scores can still tip the balance in tight cut-point environments, contributing to Star lifts, bonus eligibility, and revenue stability.
Why Tenths of a Point Decide Star Ratings
Star Ratings are often viewed in half-star increments (e.g., 3.5 to 4.0), but victories occur in tenths. CMS sets cut points (thresholds) for each measure using statistical methods like percentile clustering for non-CAHPS measures and percentile-based significance testing for CAHPS measures (e.g., 15th, 30th, 60th, 80th percentiles with adjustments for significance against national averages).
With tighter cut points and greater emphasis on outcomes, small gains in CAHPS or clinical quality increasingly determine Star movement. The 2026 changes shifted focus but did not eliminate CAHPS’s role; plans near thresholds must still prioritize it.
Why a 0.2-Point CAHPS Improvement Is Not Small
A 0.2-point improvement in CAHPS may appear incremental, but within the Star Ratings framework it can be decisive.
That marginal gain can:
- Push a contract over a Star threshold in clustered cut points.
- Convert gains in clinical quality (e.g., diabetes care, blood pressure control) into higher Stars.
- Secure or increase Quality Bonus Payments, which provide additional revenue per member per month (PMPM).
- Reduce member churn by improving satisfaction and retention.
Even at 2× weighting, CAHPS influences 8–10 measures and contributes roughly 20% or more to the overall score in many analyses, making it decisive for bonus eligibility.
How CAHPS Scores Flow Into Star Ratings
CAHPS does not add Stars directly but follows a structured process:
- Member survey responses form composite CAHPS measures.
- Case-mix adjustment accounts for demographics, health status, dual eligibility, and other factors via logistic regression (e.g., covariates like age, education, and proxy use).
- Reliability adjustments stabilize results using significance testing and standard errors (reliability thresholds ≥0.60; low reliability affects borderline Star assignments).
- Adjusted scores undergo national clustering or percentile ranking to set cut points.
- Each CAHPS measure contributes a 2× weight to the overall Star Rating.
This pipeline ensures fair comparisons, with CAHPS affecting domains like Member Experience with Health Plan (Part C) and Drug Plan (Part D), thus making it one of the largest single clusters of related measures in the Stars program.
What Changed With the 2× CAHPS Weight and What Didn’t
CMS confirmed the reduction from 4× to 2× for patient experience/complaints and access measures (including CAHPS) beginning with 2026 Star Ratings, based on prior rulemaking.
What changed:
- Isolated CAHPS gains have less standalone impact
- CAHPS can no longer single-handedly elevate a contract to a higher tier
What did not change:
- CAHPS affects multiple measures at once
- It remains one of the more controllable and faster-moving levers within a Star cycle
- Weak CAHPS performance can still block Star gains, even when clinical metrics improve
CAHPS has evolved into a multiplier: strong clinical quality needs solid member experience to fully convert into Stars and revenue.
CAHPS as a Multiplier in the Modern Stars Model
In the current Star environment, the equation looks different:
- Strong clinical quality without solid CAHPS → limited Star upside.
- Strong clinical quality with solid CAHPS → meaningful Star and revenue lift.
This multiplier effect ensures investments in care delivery, adherence, and operations pay off.
A Simple Revenue Illustration
For a mid-sized MA-PD contract (with approx. 100,000 members), a 0.2-point CAHPS improvement might add 0.04–0.06 points to the overall Star Rating. Crossing from 3.5 to 4.0 Stars can unlock Quality Bonus Payments (QBPs) of $40–$100 Per Member Per Month (PMPM), equating to $48–$120 million annually.
While CAHPS rarely drives movement alone, it often determines whether other gains translate financially. Industry estimates highlight billions in potential QBP losses from Star shifts, underscoring the stakes.
Why Plans Continue to Invest in CAHPS
Despite reduced weightage, CAHPS still stays attractive because it is:
- More operationally controllable than many outcome measures
- Faster to influence than clinical metrics
- Tied to retention and satisfaction
- A stabilizer amid competitive pressures
For plans operating near critical cut points, CAHPS improvements often make the difference between realizing gains and leaving value on the table.
The Bottom Line
A 0.2-point CAHPS improvement is not about optics. It is about probability.
- The probability of crossing a Star threshold.
- The probability of securing bonus eligibility.
- The probability that investments in quality actually pay off.
In a system where tenths matter more than ever, CAHPS still plays a critical—if more nuanced—role in the journey from Stars to revenue.
What This Means for Plans and Where Analytics Makes the Difference
As CAHPS plays a more nuanced role in Star Ratings, the challenge for plans is no longer whether CAHPS matters, but how precisely to act on it.
At MathCo, we help plans translate CAHPS data into Star-relevant, decision-ready insight—connecting experience drivers to cut-point sensitivity, improvement feasibility, and revenue impact. The focus is not on optimizing CAHPS in isolation, but on ensuring that every tenth of improvement is intentional, defensible, and aligned with how CMS actually calculates Stars.
In a tighter Stars environment, precision and not volume—is what moves the needle.
Pharma Competitive Intelligence: Why the Industry Is Still Missing the Signals That Matter